Completed

NCT Number: NCT04744688

Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has prolonged the survival substantially for selected patients with peritoneal metastases from colorectal cancer.Bleeding and thromboembolic disease have been reported as postoperative complications related to this advanced open surgical treatment. However, perioperative changes in coagulation and fibrinolysis are only sparsely reported in the literature.The mainstay of treatment with curative intend of none-advanced colorectal cancer is minimally invasive laparoscopic surgery followed by adjuvant chemotherapy. The approach is considered associated with a lower risk of thromboembolic disease than open surgery. Despite differences in extent of surgery and thromboembolic risk the same extended thromboprophylaxis regimen for 28 days is currently prescribed to patients undergoing cytoreductive surgery with HIPEC as well as minimally invasive rectal cancer resection. This study aims to investigate all parts of the coagulation system and fibrinolysis, and thereby thromboembolic risk and potential bleeding in two groups of patients with different extent of surgical trauma: 1) Colorectal cancer patients undergoing cytoreductive surgery with HIPEC and 2) rectal cancer patients undergoing minimal invasive rectal cancer resection. Our hypothesis is that patients undergoing cytoreductive surgery with HIPEC are exposed to more aggravated alterations of coagulation and fibrinolysis than patients undergoing minimally invasive rectal cancer resection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peritoneal Metastases Abdominal Neoplasms Bleeding Cardiovascular Diseases Coagulation Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Colorectal Neoplasms Malignant Cytoreductive Surgery Digestive System Diseases Digestive System Neoplasms Embolism and Thrombosis Gastrointestinal Diseases Gastrointestinal Neoplasms Hemorrhage Intestinal Diseases Intestinal Neoplasms Laparoscopic Surgery Laparoscopy Minimally Invasive Surgical Procedures Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Peritoneal Carcinomatosis Peritoneal Diseases Peritoneal Neoplasms Postoperative Complications Rectal Diseases Rectal Neoplasms Surgical Oncology Surgical Procedures, Operative Thromboembolism Thrombosis Vascular Diseases Venous Thromboembolism

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aarhus University Hospital, Aarhus, Aarhus N, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cytoreductive surgery with HIPEC patients:

Able to give informed consent
Age ≥ 18 years
Diagnosed with peritoneal metastases from colorectal cancer
Planned to undergo cytoreductive surgery with HIPEC

Minimally invasive rectal cancer patients:

Able to give informed consent
Age ≥ 18 years
Diagnosed with rectal cancer
Planned to undergo minimal invasive rectal cancer resection with one of: total mesorectal excision, partial mesorectal excision or abdominoperineal excision

Exclusion criteria

(both groups):

Thromboembolic event within 90 days before surgery
Secondary malignancy within previous 5 years or concomitant, except non-melanoma skin cancer.

Treatment and study plan

Primary outcomes

The difference between changes in concentration of prothrombin fragment 1+2.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Secondary outcomes

The difference between changes in platelet concentration from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of immature platelets from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of plasma selectin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in activated partial thromboplastin time "APTT" (seconds) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in international normalized ratio "INR" (seconds) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of plasma fibrinogen from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of coagulation factor VIII from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of von wildebrand factor from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of thrombin-antithrombin complex from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in thrombin generation before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Thrombin generation will be measured by:

Lagtime (min), time to peak (min), peak thrombin (nM) and endogenous thrombin potential (nM*min).
The difference between changes of fibrin clot structure from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference between changes of fibrin clot structure from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Fibrin clot structure will be measured by clot maximum, absorbance (arbitrary units), network density, lysis time (seconds), lysis area (balance between clot formation and lysis).
The difference between changes in concentration of plasminogen activator inhibitor-1 from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of fibrin d-dimer from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in global hemostasis by Rotational thromboelastometry (ROTEM) from before surgery to the end of surgery (both groups)

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery (both groups).

ROTEM will include EXTEM, INTEM, FIBTEM, and APTEM by clotting time (seconds), clot formation time (seconds), alpha-angle (degrees), amplitude 10 min after clotting time (mm), maximum clot firmness (mm), lysis index 30 min after clotting time (mm), maximum lysis (mm).
The difference between changes in concentration of syndecan-1 from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of sE-selectin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of soluble thrombomodulin. from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of hemoglobin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration of leucocytes from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.
The difference between changes in concentration C-reactive protein (CRP) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from before surgery to the end of surgery in cytoreductive surgery.
The difference between changes in concentration of prothrombin fragment 1+2. from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end HIPEC.
The difference between changes in platelet concentration from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of immature platelets from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in activated partial thromboplastin time "aPTT" (seconds) from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in activated international normalized ratio "INR" (seconds) from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of plasma fibrinogen from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of coagulation factor VIII from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of von wildebrand factor from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of thrombin-antithrombin complex from the end of cytoreductive surgery to the end HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in thrombin generation from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. Thrombin generation will be measured by: Lagtime (min), time to peak (min), peak thrombin (nM) and endogenous thrombin potential (nM*min).
The difference between changes of fibrin clot structure from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC. Fibrin clot structure will be measured by clot maximum, absorbance (arbitrary units), network density, lysis time (seconds), lysis area (balance between clot formation and lysis).
The difference between changes in concentration of plasminogen activator inhibitor-1 from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of fibrin d-dimer from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of global hemostasis measured by Rotational thromboelastometry (ROTEM) from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery to the end HIPEC.

ROTEM will include EXTEM, INTEM, FIBTEM, and APTEM by clotting time (seconds), clot formation time (seconds), alpha-angle (degrees), amplitude 10 min after clotting time (mm), maximum clot firmness (mm), lysis index 30 min after clotting time (mm), maximum lysis (mm).
The difference between changes in concentration of syndecan-1 from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end HIPEC.
The difference between changes in concentration of sE-selectin from the end of cytoreductive surgery to the end of HIPEC

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of soluble thrombomodulin from the end of cytoreductive surgery to the end of HIPEC

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of hemoglobin from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of leucocytes from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years.

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
The difference between changes in concentration of C-reactive protein (CRP) from the end of cytoreductive surgery to the end of HIPEC.

Time frame: Data will be analyzed, assessed, and presented within three years

The difference will be measured in blood samples from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.
Incidence of deep vein thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing minimally invasive rectal cancer resection.

Time frame: Data will be analyzed, assessed, and presented within three years

Bilateral doppler ultrasonography of the veins in the lower extremities.The scan will be performed within the postoperative period from day 3 to day 7.
Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC

Time frame: Data will be analyzed, assessed, and presented within three years

Bilateral doppler ultrasonography of the veins in the lower extremities.The scan will be performed within the postoperative period from day 3 to day 7.

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Acronym: CONTEST

Important dates

Study start: 2021
Primary completion: 2023
Study completion: 2024
First posted: Feb 9, 2021
Registry last updated: May 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

NCT02758951

Abdominal Neoplasms, Body Temperature Changes

Genk, Flanders, Belgium

View Trial Details

Active, Not Recruiting

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

NCT05277766

Abdominal Neoplasms, Adenocarcinoma

Ghent, East-Flanders, Belgium

View Trial Details

Active, Not Recruiting

Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms

NCT05623787

Abdominal Neoplasms, Appendiceal Neoplasms

Montreal, Quebec, Canada

View Trial Details

Recruiting

Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients

NCT03280511

Abdominal Neoplasms, Colo-rectal Cancer

Odense, Denmark

View Trial Details

Key information

Conditions

Age range

Sex eligibility

Study type

Primary location

Who can participate

Treatment and study plan

Primary outcomes

The difference between changes in concentration of prothrombin fragment 1+2.

Secondary outcomes

The difference between changes in platelet concentration from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of immature platelets from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of plasma selectin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in activated partial thromboplastin time "APTT" (seconds) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in international normalized ratio "INR" (seconds) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of plasma fibrinogen from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of coagulation factor VIII from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of von wildebrand factor from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of thrombin-antithrombin complex from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in thrombin generation before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes of fibrin clot structure from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of plasminogen activator inhibitor-1 from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of fibrin d-dimer from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in global hemostasis by Rotational thromboelastometry (ROTEM) from before surgery to the end of surgery (both groups)

The difference between changes in concentration of syndecan-1 from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of sE-selectin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of soluble thrombomodulin. from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of hemoglobin from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of leucocytes from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration C-reactive protein (CRP) from before surgery to the end of surgery in cytoreductive surgery with HIPEC patients and patients undergoing minimally invasive rectal cancer resection.

The difference between changes in concentration of prothrombin fragment 1+2. from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes in platelet concentration from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in concentration of immature platelets from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in activated partial thromboplastin time "aPTT" (seconds) from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in activated international normalized ratio "INR" (seconds) from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in concentration of plasma fibrinogen from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in concentration of coagulation factor VIII from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in concentration of von wildebrand factor from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in concentration of thrombin-antithrombin complex from the end of cytoreductive surgery to the end HIPEC.

The difference between changes in thrombin generation from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes of fibrin clot structure from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes in concentration of plasminogen activator inhibitor-1 from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes in concentration of fibrin d-dimer from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes in concentration of global hemostasis measured by Rotational thromboelastometry (ROTEM) from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.

The difference between changes in concentration of syndecan-1 from the end of cytoreductive surgery (before HIPEC) to the end of HIPEC.

The difference between changes in concentration of sE-selectin from the end of cytoreductive surgery to the end of HIPEC

The difference between changes in concentration of soluble thrombomodulin from the end of cytoreductive surgery to the end of HIPEC

The difference between changes in concentration of hemoglobin from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes in concentration of leucocytes from the end of cytoreductive surgery to the end of HIPEC.

The difference between changes in concentration of C-reactive protein (CRP) from the end of cytoreductive surgery to the end of HIPEC.

Incidence of deep vein thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing minimally invasive rectal cancer resection.

Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC

Sponsors and collaborators

Lead sponsor

Registry information

Important dates

Related clinical trials

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms

Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients